| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169928 | HARMONY | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications |
Feb, 2020
(4 years ago) | |
| US8207197 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine |
Mar, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7910605 | HARMONY | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications |
Sep, 2022
(1 year, 7 months ago) | |
| US8354430 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine |
Feb, 2026
(1 year, 9 months from now) | |
| US8486947 | HARMONY | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands |
Sep, 2029
(5 years from now) | |
Wakix is owned by Harmony.
Wakix contains Pitolisant Hydrochloride.
Wakix has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Wakix are:
- US7910605
- US7169928
Wakix was authorised for market use on 14 August, 2019.
Wakix is available in tablet;oral dosage forms.
Wakix can be used as method of treating cataplexy in patients with narcolepsy.
Drug patent challenges can be filed against Wakix from 15 August, 2023.
The generics of Wakix are possible to be released after 07 March, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2024 |
| Orphan Drug Exclusivity(ODE-255) | Aug 14, 2026 |
| Orphan Drug Exclusivity(ODE-331) | Oct 13, 2027 |
| New Indication(I-846) | Oct 13, 2023 |
Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient
NCE-1 date: 15 August, 2023
Market Authorisation Date: 14 August, 2019
Treatment: Method of treating cataplexy in patients with narcolepsy
Dosage: TABLET;ORAL
WAKIX family patents
